Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate whether simtuzumab (GS-6624) is effective at preventing the progression of liver fibrosis in adults with primary sclerosing cholangitis (PSC).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01672853
Study type Interventional
Source Gilead Sciences
Contact
Status Completed
Phase Phase 2
Start date March 4, 2013
Completion date August 24, 2016

See also
  Status Clinical Trial Phase
Completed NCT05082779 - Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159 Phase 1
Completed NCT06037577 - Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects Phase 1
Completed NCT02061540 - Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis Phase 2
Completed NCT01819766 - Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease N/A
Active, not recruiting NCT01161992 - Genomics of Primary Sclerosing Cholangitis (PSC)
Completed NCT02808312 - Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function Phase 1
Completed NCT03333928 - A POC and Dose-Ranging Study of HTD1801 in PSC Patients Phase 2
Completed NCT02177136 - Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC) Phase 2
Completed NCT03766035 - Cholangioscopy in Primary Sclerosing Cholangitis (PSC)
Completed NCT01695174 - A Pilot Study of Xifaxan to Treat Patients With PSC Phase 1
Recruiting NCT06026865 - S-adenosylmethionine (SAMe) in Patients With Primary Sclerosing Cholangitis (PSC) N/A